<DOC>
	<DOCNO>NCT01851408</DOCNO>
	<brief_summary>This phase II portion trial study side effect best dose temsirolimus give together sorafenib see well work treat patient metastatic , recurrent , unresectable melanoma . Sorafenib temsirolimus may stop growth tumor cell block enzymes need cell growth . Sorafenib may also stop growth tumor cell block blood flow tumor . Giving sorafenib together temsirolimus may kill tumor cell .</brief_summary>
	<brief_title>Sorafenib Temsirolimus Treating Patients With Metastatic , Recurrent , Unresectable Melanoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : - To evaluate clinical activity , term overall response rate ( complete partial response ) , regimen patient . ( Phase II ) - To evaluate vivo biological activity regimen patient . SECONDARY OBJECTIVES : I . To determine progression-free survival overall survival patient treat regimen . II . To determine safety toxicity regimen patient . III . To Determine population pharmacokinetics regimen patient . IV . To correlate tumor blood biomarkers clinical outcome patient treat regimen . OUTLINE : Upon completion multicenter , phase I , dose-escalation study follow follow phase II , open-label study . Patients receive temsirolimus IV 30 minute day 1 , 8 , 15 , 22 oral sorafenib twice daily day 1-28 . Treatment course repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3-6 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm melanoma , meet 1 follow criterion : recurrent unresectable stage III disease , stage IV disease , nonchoroidal origin . Tumor must accessible biopsy unless appropriate tumor sample collection occur within past 3 month patient agrees provide sample study . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Bilirubin normal Creatinine normal creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day completion study treatment . No history allergic reaction attribute compound similar chemical biological composition sorafenib temsirolimus . No uncontrolled hypertension , define systolic blood pressure &gt; 140 mm Hg 2 separate day &lt; 1 week prior study entry OR diastolic pressure &gt; 90 mm Hg 2 separate day &lt; 1 week prior study entry . No evidence bleed diathesis coagulopathy . No condition would impair ability swallow pill ( e.g. , gastrointestinal tract disease result inability take oral medication ; requirement IV alimentation ; active peptic ulcer disease ) . No uncontrolled illness include , limited , follow : ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia psychiatric illness social situation would limit study compliance . No traumatic injury within past 3 week . No 1 prior systemic chemotherapy regimen metastatic melanoma ( Phase II ) . No prior sorafenib , temsirolimus , agent target raf , vascular endothelial growth factor ( VEGF ) /VEGF receptor , mTOR ( Phase II ) . No prior surgical procedure affect absorption . At least 3 week since prior major surgery . At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) melanoma recover . At least 4 week since prior radiotherapy recover . Prior biologic immunotherapeutic regimen allow . Prior regional chemotherapy regimen ( e.g. , isolated limb perfusion ) allow 1 prior regional chemotherapy regimen allow target lesion within prior regional treatment field . No concurrent enzymeinducing antiepileptic drug include , limited , follow : phenytoin , carbamazepine , phenobarbital , rifampin Hypericum perforatum ( St. John 's wort ) . No concurrent prophylactic hematopoietic colonystimulating factor . No concurrent investigational agent . No concurrent anticancer agent therapies cancer . No concurrent fulldose anticoagulation ( i.e. , warfarin , IV heparin , lowmolecular weight heparin ) . No concurrent grapefruit grapefruit juice . No concurrent combination antiretroviral therapy HIVpositive patient . Concurrent prophylactic anticoagulation therapy ( e.g. , lowdose warfarin ) allow provide prothrombin time ( PT ) international normalize ratio ( INR ) &lt; 1.1 time upper limit normal ( ULN ) . Unidimensionally measurable disease &gt; = 20 mm conventional technique &gt; = 10 mm spiral compute tomography ( CT ) scan ( long diameter record ) margin visible cutaneous metastatic lesion clearly define measure least one dimension &gt; = 10 mm . No known brain metastasis unless follow criterion meet : radiographical evidence recurrence brain &gt; = 3 month complete resection brain metastasis , asymptomatic brain metastasis stable &gt; = 3 month since wholebrain radiation therapy and/or stereotactic radiosurgery must require steroid brain metastasis . White Blood Count ( WBC ) &gt; = 3,000/mm³ Absolute neutrophil count &gt; = 1,500/mm³ Platelet count &gt; = 100,000/mm³ Serum cholesterol = &lt; 350 mg/dL Triglycerides = &lt; 400 mg/dL Alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) = &lt; 2.5 time upper limit normal . No peripheral neuropathy &gt; grade 2 . At least 5 year since prior chemotherapy type cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Sorafenib</keyword>
	<keyword>Temsirolimus</keyword>
	<keyword>Stage IV</keyword>
	<keyword>recurrent</keyword>
	<keyword>unresectable</keyword>
	<keyword>non-choroidal origin</keyword>
	<keyword>CCI-779</keyword>
	<keyword>BAY43-9006</keyword>
	<keyword>metastatic melanoma</keyword>
</DOC>